Difference between revisions of "Langerhans cell histiocytosis"
m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
||
Line 27: | Line 27: | ||
===Regimen {{#subobject:#3c6b84|Variant=1}}=== | ===Regimen {{#subobject:#3c6b84|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 54: | Line 54: | ||
===Protocol {{#subobject:#7ace0e|Variant=1}}=== | ===Protocol {{#subobject:#7ace0e|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 91: | Line 91: | ||
===Regimen {{#subobject:#f569ce|Variant=1}}=== | ===Regimen {{#subobject:#f569ce|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 119: | Line 119: | ||
===Protocol {{#subobject:#bf6a74|Variant=1}}=== | ===Protocol {{#subobject:#bf6a74|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
Revision as of 02:07, 26 September 2020
Section editor | |
---|---|
Gaurav Goyal, MD UAB Birmingham, AL GauravGoyalMD |
12 regimens on this page
12 variants on this page
|
Note: the majority of the regimens on this page are intended for multi-system Langerhans cell histiocytosis (MS-LCH); many patients with other forms of LCH, such as pulmonary (PLCH) do not necessarily need antineoplastic treatment.
Guidelines
Euro-Histio-Net
- 2013: Management of adult patients with Langerhans cell histiocytosis: Recommendations from an expert panel on behalf of Euro-Histio-Net
- 2013: Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
Untreated
Etoposide & Prednisone
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gadner et al. 2001 (LCH-I) | Phase III (E-switch-ic) | Vinblastine & Prednisone | Did not meet efficacy endpoints |
To be completed
Chemotherapy
References
- Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Pötschger U, Pritchard J, Ladisch S; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34. Erratum in: J Pediatr 2001 Jul;139(1):170. link to original article PubMed
Etoposide, Vinblastine, Prednisone
back to top |
Protocol
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gadner et al. 2007 (LCH-II) | Phase III (E-esc) | Vinblastine & Prednisone | Did not meet primary endpoint of rapid response |
Total duration of therapy is 24 weeks.
Chemotherapy, initial
- Etoposide (Vepesid) 150 mg/m2 IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36
- Vinblastine (Velban) 6 mg/m2 IV bolus once per day on days 1, 8, 15, 22, 29, 36
- Prednisone (Sterapred) 40 mg/m2/day split three times per day for 4 weeks, then tapering off over 2 weeks
6-week course, followed by:
Chemotherapy, continuation
- Etoposide (Vepesid) 150 mg/m2 IV over 60 minutes once on day 1
- Vinblastine (Velban) 6 mg/m2 IV bolus once on day 1
- Prednisone (Sterapred) 40 mg/m2/day split three times per day on days 1 to 5
21-day cycle for 6 cycles
References
- Gadner H, Grois N, Pötschger U, Minkov M, Aricò M, Braier J, Broadbent V, Donadieu J, Henter JI, McCarter R, Ladisch S; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62. Epub 2007 Dec 18. link to original article contains verified protocol PubMed
Methotrexate, Vinblastine, Prednisone
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gadner et al. 2013 (LCH-III) | Phase III (E-esc) | Vinblastine & Prednisone | Did not meet primary endpoint of early progression at week 6 and response at week 12 |
To be completed
Chemotherapy
References
- Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. Epub 2013 Apr 15. link to original article PubMed
Vinblastine & Prednisone
back to top |
Protocol
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gadner et al. 2001 (LCH-I) | Phase III (E-switch-ic) | Etoposide & Prednisone | Did not meet efficacy endpoints |
Gadner et al. 2007 (LCH-II) | Phase III (C) | Etoposide, Vinblastine, Prednisone | Did not meet primary endpoint of rapid response |
Gadner et al. 2013 (LCH-III) | Phase III (C) | Methotrexate, Vinblastine, Prednisone | Did not meet primary endpoint of early progression at week 6 and response at week 12 |
Total duration of therapy is 24 weeks, in LCH-II.
Chemotherapy, initial
- Vinblastine (Velban) 6 mg/m2 IV bolus once per day on days 1, 8, 15, 22, 29, 36
- Prednisone (Sterapred) 40 mg/m2/day split three times per day for 4 weeks, then tapering off over 2 weeks
6-week course, followed by:
Chemotherapy, continuation
- Vinblastine (Velban) 6 mg/m2 IV bolus once on day 1
- Prednisone (Sterapred) 40 mg/m2/day split three times per day on days 1 to 5
21-day cycle for 6 cycles
References
- Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Pötschger U, Pritchard J, Ladisch S; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34. Erratum in: J Pediatr 2001 Jul;139(1):170. link to original article PubMed
- Gadner H, Grois N, Pötschger U, Minkov M, Aricò M, Braier J, Broadbent V, Donadieu J, Henter JI, McCarter R, Ladisch S; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62. Epub 2007 Dec 18. link to original article contains verified protocol PubMed
- Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. Epub 2013 Apr 15. link to original article PubMed
Relapsed or refractory
Cladribine monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Weitzman et al. 2009 (LCH-S-98) | Phase II |
To be completed
Chemotherapy
References
- LCH-S-98: Weitzman S, Braier J, Donadieu J, Egeler RM, Grois N, Ladisch S, Pötschger U, Webb D, Whitlock J, Arceci RJ. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH): results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009 Dec 15;53(7):1271-6. link to original article PubMed
Cladribine & Cytarabine
back to top |
Regimen
Study | Evidence |
---|---|
Donadieu et al. 2015 (LCH-S-2005) | Phase II |
Chemotherapy
- Cladribine (Leustatin) 9 mg/m2 IV over 2 hours once per day on days 2 to 6, should not be administered simultaneously with cytarabine
- Children weighing less than 10 kg received a dose of 0.3 mg/kg/day
- Cytarabine (Ara-C) 500 mg/m2 IV over 2 hours twice per day on days 1 to 5, should not be administered simultaneously with cladribine
35-day cycle for 2 or more cycles
Subsequent treatment
- Patients with a "good response": Cladribine consolidation
References
- LCH-S-2005: Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23. Epub 2015 Jul 20. link to original article contains verified protocol link to PMC article PubMed
Cobimetinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Diamond et al. 2019 (MSK 15-216) | Pilot, <20 pts in this arm |
Note: there were N=2 patients with LCH; it was unclear if they were untreated or previously treated.
Targeted therapy
- Cobimetinib (Cotellic) 60 mg PO once per day on days 1 to 21
28-day cycles
References
- MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains verified protocol link to PMC article PubMed
Vemurafenib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Hyman et al. 2015 (VE-BASKET) | Phase II, <20 pts in this arm |
This was part of a basket trial, all patients had BRAF p.V600E mutations. A minority (7/18, 39%) of participants were untreated.
Targeted therapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
Duration of treatment not specified
References
- VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-736. link to original article contains verified protocol link to PMC article PubMed
Relapsed or refractory, consolidation
Cladribine monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Donadieu et al. 2015 (LCH-S-2005) | Phase II |
Preceding treatment
Chemotherapy
- Cladribine (Leustatin) 5 mg/m2 IV once per day on days 1 to 3
21-day cycle for 2 cycles
Subsequent treatment
References
- LCH-S-2005: Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23. Epub 2015 Jul 20. link to original article contains verified protocol link to PMC article PubMed
Relapsed or refractory, maintenance
Mercaptopurine, Methotrexate, Vinblastine, Prednisolone
back to top |
Regimen
Study | Evidence |
---|---|
Donadieu et al. 2015 (LCH-S-2005) | Phase II |
Preceding treatment
- Cladribine x 2
Chemotherapy
- Mercaptopurine (6-MP) 50 mg/m2 PO once per day
- Methotrexate (MTX) 20 mg/m2 PO once per day on days 1 & 8
- Vinblastine (Velban) as follows:
- Cycles 1 to 13: 6 mg/m2 IV once on day 1
- Prednisolone (Millipred) as follows:
- Cycles 1 to 13: 40 mg/m2 PO once per day on days 1 to 5
14-day cycles for 39 cycles (18 months)
References
- LCH-S-2005: Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23. Epub 2015 Jul 20. link to original article contains verified protocol link to PMC article PubMed